Kathryn E Beckermann Pradeep C Jolly Ju Y Kim Jennifer Bordeaux Igor Puzanov W Kimryn Rathmell Douglas B Johnson
10.1186/s40425-016-0206-1
J Immunother Cancer
2017 Jan 17;5:1.
nivolumab pd-1 renal cell carcinoma renal medullary carcinoma
CC BY
https://pubmed.ncbi.nlm.nih.gov/28105368/
Carcinoma, Medullary / therapy Kidney Neoplasms / therapy Programmed Cell Death 1 Receptor / immunology Tumor Microenvironment / drug effects
Carcinoma, Medullary / therapy Kidney Neoplasms / therapy Programmed Cell Death 1 Receptor / immunology Tumor Microenvironment / drug effects Case Reports Adult Antibodies, Monoclonal / administration & dosage Carcinoma, Medullary / genetics Carcinoma, Medullary / immunology Carcinoma, Medullary / pathology Female Humans Kidney Neoplasms / genetics Kidney Neoplasms / immunology Male Neoplasm Metastasis Nivolumab Programmed Cell Death 1 Receptor / antagonists & inhibitors Programmed Cell Death 1 Receptor / genetics Tumor Microenvironment / immunology Antibodies, Monoclonal PDCD1 protein, human Programmed Cell Death 1 Receptor Nivolumab
PMC5240268
28105368
Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma
2017